title: Evaluation of total hepatocellular cancer lifespan, including both clinically evident and preclinical development, using combined network phenotyping strategy and fisher information analysis.
abstract: We previously showed that for hepatocellular cancer (HCC) prognostication, disease parameters need to be considered within a total personal clinical context. This requires preserving the coherence of data values, observed simultaneously for each patient during baseline diagnostic evaluation. Application of the Network Phenotyping Strategy (NPS) provided quantitative descriptors of these patient coherences. Combination of these descriptors with Fisher information about the patient tumor mass and the histogram of the tumor masses in the whole cohort permitted estimation of the time from disease onset until clinical diagnosis (t(baseline)). We found faster growth of smaller tumors having total masses<70 (80% of cohort) which involved about three times more interacting cellular processes than were observed for slower growing larger tumors (20% of cohort) with total masses>70. Combining the clinical survival and t(baseline) normalized all HCC patients to a common 1,045 days of mean total disease duration (t(baseline) plus post diagnosis survival). We also found a simple relationship between the baseline clinical status, t(baseline), and survival. Every difference between individual patient baseline clinical profiles and special coherent clinical status (HL1) reduced the above common overall survival (OVS) by 65 days. In summary, we showed that HCC patients with any given tumor can best have their tumor biology understood, when account is taken of the total clinical and liver contexts, and with knowing the point in the tumor history when an HCC diagnosis is made. This ability to compute the t(baseline) from standard clinical data brings us closer to calculating survival from diagnosis of individual HCC patients.
authors.affiliation: Department of Medicine and Center for Craniofacial and Dental Genetics, University of Pittsburgh, Pittsburgh, PA; Computer Science Institute (IUUK) of Charles University Prague, Czech Republic.
authors.forename: Petr
authors.initials: P
authors.lastname: Pančoška
authors.affiliation: Department of Chemical Physics and Optics, Faculty of Mathematics and Physics, Charles University Prague, Czech Republic.
authors.forename: Lubomír
authors.initials: L
authors.lastname: Skála
authors.affiliation: Computer Science Institute (IUUK) of Charles University Prague, Czech Republic.
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Nešetřil
authors.affiliation: Department of Gastroenterology and Liver Diseases Tel-Aviv Sourasky Medical Center Tel Aviv, Israel. Electronic address: brianicarr@hotmail.com.
authors.forename: Brian I
authors.initials: BI
authors.lastname: Carr
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D011379:Prognosis
references.citation: Ann Surg Oncol. 2008 Dec;15(12):3503-11
references.pmid: 18777193
references.citation: Semin Oncol. 2014 Jun;41(3):406-414
references.pmid: 25023357
references.citation: World J Surg. 2007 Jun;31(6):1243-8
references.pmid: 17440771
references.citation: Int J Mol Sci. 2014 May 27;15(6):9422-58
references.pmid: 24871369
references.citation: J Gastrointest Dig Syst. 2013 Mar 2;Suppl 12:
references.pmid: 23956952
references.citation: Hepatogastroenterology. 2013 Sep;60(126):1433-7
references.pmid: 23933936
references.citation: Semin Cancer Biol. 2015 Feb;30:60-9
references.pmid: 24657638
references.citation: Growth Dev Aging. 1989 Spring-Summer;53(1-2):25-33
references.pmid: 2807642
references.citation: CPT Pharmacometrics Syst Pharmacol. 2014 May 07;3:e113
references.pmid: 24806032
references.citation: Semin Cancer Biol. 2015 Feb;30:70-8
references.pmid: 24793698
references.citation: Int J Surg. 2013;11(10):1078-82
references.pmid: 24129124
references.citation: PLoS One. 2014 Aug 18;9(8):e103228
references.pmid: 25133493
references.citation: PLoS One. 2014 Mar 07;9(3):e88182
references.pmid: 24609114
references.citation: BMC Gastroenterol. 2012 Jun 08;12:64
references.pmid: 22681852
references.citation: Oncology. 2012;83(6):339-45
references.pmid: 23006937
references.citation: Hepatol Int. 2009 Dec 24;4(1):396-405
references.pmid: 20305756
references.citation: Semin Oncol. 2010 Apr;37(2):170-81
references.pmid: 20494709
references.citation: Hepatology. 2015 Jan;61(1):191-9
references.pmid: 25142309
references.citation: Hepatogastroenterology. 2003 Nov-Dec;50(54):2022-7
references.pmid: 14696457
references.citation: Radiat Environ Biophys. 1987;26(2):125-41
references.pmid: 3615807
references.citation: Cancer. 2009 Jul 1;115(13):2844-52
references.pmid: 19402168
references.citation: J Clin Pathol. 1987 Sep;40(9):1055-63
references.pmid: 3312299
references.citation: Gastroenterology. 2013 Mar;144(3):512-27
references.pmid: 23313965